Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro by Shah, Mohsin et al.
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 
 
 
 
 
 
 
Shah, M., Gallipoli, P. , Lyons, J., Holyoake, T.L. , and Jorgensen, 
H.G. (2012) Effects of the novel aurora kinase/JAK inhibitor, AT9283 
and imatinib on Philadelphia positive cells in vitro. Blood, Cells, 
Molecules and Diseases, 48 (3). pp. 199-201. ISSN 1079-9796  
 
http://eprints.gla.ac.uk/64199/ 
 
Deposited on: 5 June 2012 
 
 
` 1 
Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on 
Philadelphia positive cells in vitro 
 
To the Editor 
 
Despite the clinical success of targeted tyrosine kinase inhibitors (TKI) such as 
imatinib (IM; Glivec, Novartis) in chronic myeloid leukaemia (CML), leukaemic 
stem cell persistence in vivo necessitates the search for novel targets for alternative 
therapeutic intervention. Several novel investigational medicinal products aimed at 
hitting cellular survival signalling pathways that are independent of BCRABL in the 
hope of increasing efficacy of TKI monotherapy in CML patients are in clinical 
development. One such target maybe Janus Kinase (JAK) 2 that plays a role in 
transducing growth factor mediated signalling through STAT5.  In CML, JAK2 can 
be directly phosphorylated by BCRABL kinase, the causative oncoprotein in CML, 
and in turn phosphorylates tyrosine 177 of BCRABL that appears necessary for its 
stabilisation and activation. However, JAK2 can also directly and independently lead 
to activation of survival/anti-apoptotic signals via growth factor receptors even when 
BCRABL kinase activity is inhibited [1,2]. JAK2, as a result, warrants further 
investigation as a potential therapeutic target in CML.  
 
We planned to reveal the relevance of JAK2 kinase in survival and proliferation of the 
human CML cell line, KCL22 using the novel multi-targeted kinase inhibitor AT9283 
(1-cyclopropyl–3[5-morpholin-4yl methyl-1H-benzomidazol-2-yl]-urea) (Astex 
Pharmaceuticals Ltd.) [3] that has already reached clinical development in solid 
tumours [4]. AT9283 has in vitro activity against multiple kinases but is active at low 
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(nanomolar) concentrations particularly against JAK2 and aurora kinases. KCL22 is a 
human BCRABL positive cell line established from the pleural effusion of a CML 
blast crisis patient [5] displaying human hyperdiploid karyotype with 3.3% polyploidy 
as described in the Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(DSMZ -German Collection of Microorganisms and Cell Cultures) (DSMZ # ACC 
519).   
 
In order to investigate AT9283 and its effects in conjunction with IM on CML cells in 
vitro, we first assayed the effect of AT9283 at varying concentrations over 24 to 96h 
to establish its IC50 (a measure of effectiveness of a compound in inhibiting biological 
or biochemical functions, here KCL22 cell proliferation). We analysed the individual 
and combined effects of AT9283 with IM, at fixed concentration, on apoptosis of 
KCL22 cells by flow cytometry (Annexin V and Via-Probe  staining). 
 
AT9283 was significantly more potent (IC50 15 ± 0.2 nM, n = 3, Figure 1A) than IM 
(IC50 is in the micromolar range), with respect to surviving cell number enumerated 
by trypan blue dye exclusion method. Total cell number counted by a dye exclusion 
method does not discriminate which cells are undergoing apoptosis as cells are scored 
as ‘live’ or ‘dead’. Bright ‘live’ cells under phase contrast microscopy are a mix of the 
most viable cells as well as those initiating programmed cell death.  We therefore next 
assayed apoptosis in response to AT9283 using a standard Annexin V / DNA staining 
protocol.  AT9283 committed cells to apoptosis at a level above background (i.e. in 
the No Drug Control) at concentrations of 30nM and above at 72h (Figure 1B).  When 
used in combination, an enhanced apoptotic response was found compared with either 
agent alone at 72h (Figure 1D).  Thus, even when BCRABL had been maximally 
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inhibited with 2µM IM, a deeper apoptotic response could be detected in KCL22 
when AT9283 was present suggesting that AT9283 can act independently of 
BCRABL to effect cell kill. AT9283 with its multitargeted profile of kinase 
inhibition, is a potent inhibitor of serine/threonine kinases targeting aurora family 
kinases as well as tyrosine kinases including JAK and ABL.  It is therefore likely that 
aurora kinase or JAK inhibition is mediating the drug effect seen here under 
conditions of maximal ABL/BCRABL kinase inhibition. Being nuclear proteins, 
aurora kinases are unlikely to interact with BCRABL. However, it is theoretically 
possible for both JAK2 [6] and BCRABL [7] to shuttle into the nucleus, although 
nuclear import of the latter occurs when the kinase is inactive [7] and to the best of 
our knowledge, there is no known direct interaction between aurora kinases and 
ABL/BCRABL or JAK. 
 
The absolute number of viable cells was calculated as cell number per mL (live trypan 
blue count) x % Annexin V / Via-Probe double negative (quadrant 4 in Figure 1C).  
It can be seen that at IC50 (15nM; as calculated by dye exclusion method), the 
absolute number of viable cells at 24h is not only less than half the count in the No 
Drug Control but less than input (2 x 105 in 1mL; Figure 1E), indicating that the drug 
is more cytotoxic than cytostatic. The cell counts are not reduced with increasing 
concentration of AT9283 up to 10nM at 72h compared to No Drug Control suggesting 
either that there is a threshold of drug concentration below which the cells can recover 
or that the drug is chemically unstable in culture over extended time frame losing its 
potency. Nonetheless, given enough of the compound (here above 15nM), there is a 
diminution in absolute number of viable cells to less than input by 72h with AT9283 
alone.  
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We explored the potential of the novel aurora kinase / JAK inhibitor, AT9283 for its 
effects on blast crisis CML cells in vitro, in combination with a TKI. We chose IM, a 
rationally designed TKI that blocks the ATP-binding site of BCRABL so suppressing 
downstream signalling, as it is currently recommended as the first-line therapy for 
CML in chronic phase by the National Comprehensive Cancer Network (NCCN) and 
European LeukemiaNet (ELN) and is the current standard of care [8]. In our 
investigation, we found that AT9283 effectively blocked CML blast crisis cell 
proliferation and was more potent than IM. More significantly, a greater degree of 
apoptosis was seen at all time intervals (24 to 72h) in response to AT9283 than IM. 
Response to IM was typically found to be slow only peaking at 72h; it was neither as 
fast nor as effective as AT9283. The IC50 of AT9283 was significantly lower being in 
the nanomolar range clearly indicating the potency of the drug. Importantly, the 
combination of AT9283 (15nM) and IM (2µM) proved to be more effective than 
either drug acting alone in increasing apoptosis and controlling cell number at 72h 
[Figure 1D&E]. We chose to use IM at 2µM at which concentration BCRABL kinase 
is maximally inhibited but death is not necessarily elicited in the inherently TKI 
resistant, KCL22. We therefore could anticipate seeing additional biological effects 
owing to the activity of AT9283 in the combination. Of note, the cells were found to 
undergo apoptosis in response to AT9283 in combination with IM suggesting that the 
former also had some drug activity that was BCRABL independent [9]. 
 
We and others have shown that despite TKI driven inhibition of BCRABL activity, 
CML cells can survive in culture leading us to believe that BCRABL dependent 
signalling pathways are not the only survival signals active in CML [10,11]. This has 
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been indirectly confirmed in the laboratory based investigation reported here by the 
increased efficacy of combining aurora kinase / JAK2 with BCRABL inhibition in our 
Ph+ cell model.  In summary, the results generated from this project emphasise the 
therapeutic potential of drugs like AT9283 in combination with TKI and potentially 
identify the JAK family as a valid target for further study in treatment of CML. 
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Figure 1A: Concentration-effect curve of AT9283 on KCL22 over 72h in vitro.  
Surviving cells were counted by trypan blue dye exclusion method after 72h treatment 
with the aurora kinase / JAK2 inhibitor, AT9283.  The number of cells was expressed 
as a percentage of the No Drug Control and plotted against the drug concentration to 
determine the IC50. Figure 1B:  Total apoptosis in AT9283 treated KCL22 cells at 
72h. AT9283 committed cells to apoptosis at a level above background (i.e. in the No 
Drug Control) at concentrations at, or above, 30nM at 72h. Figure 1C: AT9283 
induces apoptosis in Ph+ blast crisis CML cell line KCL22 in vitro. Representative 
flow cytometry dot plots of KCL22 cells either untreated (far left panel, No Drug 
Control), or treated with AT9283 15nM (left panel), or IM 2µM (right panel), or the 
combination of AT9283 plus IM (far right panel) and stained for apoptosis. Q2 events 
are both Annexin-V and Via-Probe positive and therefore indicative of cells in late 
apoptosis. Q3 events are Annexin-V positive and Via-Probe negative and are 
indicative of cells undergoing early apoptosis, the most viable cells are in Q4. Total 
apoptosis would be given as the sum of events in Q2 and Q3. Figure 1D: Increased 
apoptotic response combination of IM and AT9283 at 72h.  When combined with 
IM, AT9283 was more effective in inducing apoptosis in KCL22 cells. First column 
AT9283 0nM / IM 0µM; second column AT9283 15nM / IM 0µM; third column 
AT9283 0nM / IM 2µM; fourth column AT9283 15nM / IM 2µM. White boxes 
represent percentage of cells in early apoptosis, black boxes are late apoptosis. Figure 
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1E: Absolute viable KCL22 cell numbers. Factoring in the apoptotic cells gives a 
more objective indication of drug activity than a simple cell count by dye exclusion in 
which cells undergoing programmed cell death may still appear viable. So the 
absolute number of viable cells (y-axis), calculated as live trypan blue count x % 
Annexin V / Via-Probe double negative, at 24h with 15nM AT9283 was not only 
less than half the count in the No Drug Control (NDC) but less than input (2 x 10 5 / 
mL; 1mL). 
` 8 
Figure 1 
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